Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New method provided by combination of human umbilical cord mesenchymal stem cells and incretin for improvement of functions of diabetes islet beta cells

A technology of mesenchymal stem cells and incretins, applied in the field of diabetes treatment, can solve the problems of increasing glucagon secretion and islet α cell proliferation, and achieve the effect of reducing islet α hyperplasia, promoting proliferation and regeneration, and improving diabetes

Inactive Publication Date: 2014-02-12
HOSPITAL ATTACHED TO QINGDAO UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, while stem cells are treating diabetes, they may also cause the proliferation of pancreatic α cells and increase the secretion of glucagon.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New method provided by combination of human umbilical cord mesenchymal stem cells and incretin for improvement of functions of diabetes islet beta cells
  • New method provided by combination of human umbilical cord mesenchymal stem cells and incretin for improvement of functions of diabetes islet beta cells
  • New method provided by combination of human umbilical cord mesenchymal stem cells and incretin for improvement of functions of diabetes islet beta cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] The technical scheme of the present invention is based on the pathogenesis of diabetes and the mechanism of stem cells and incretin (GLP-1 receptor agonist and DPP-4 inhibitor) in treating diabetes, thus proposing that the joint application of the two can improve insulin resistance of pancreatic islets. β-cell function, while reducing blood sugar, it can also reduce the proliferation of pancreatic α-cells and inhibit the secretion of glucagon.

[0021] In the method of the present invention, human umbilical cord mesenchymal stem cells are transplanted into the body by intravenous or interventional infusion, wherein the number of cells infused intravenously is 3×10 7 , interventional infusion, cell number: 1.5×10 7 , infused twice in a course of treatment with an interval of 1 month. The GLP-1 receptor agonist is injected subcutaneously, and the DPP-4 inhibitor is taken orally, and the dosage refers to the drug instruction.

[0022] In order to better describe the test...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A new method for improvement of functions of diabetes islet beta cells is provided by combination of human umbilical cord mesenchymal stem cells and incretin, and the new method is as follows: on the basis of application of the human umbilical cord mesenchymal stem cells for treatment of type-1 and type-2 diabetes, the incretin (GLP-1 (glucagon-like peptide-1) receptor agonist and DPP-4 (dipeptidyl peptidase-4) inhibitor) is combined. The new method can promote islet beta cell proliferation and regeneration, improve the functions of the islet beta cells, reduce blood sugar and glycated hemoglobin, reduce islet alpha hyperplasia and inhibit glucagon secretion, and thus playing a synergy effect.

Description

technical field [0001] The invention relates to a method for treating diabetes, in particular to a method for promoting the proliferation of pancreatic beta cells, improving the function of pancreatic islets, reducing the proliferation of pancreatic islet alpha cells and inhibiting the secretion of glucagon. Background technique [0002] Diabetes mellitus is a group of clinical syndromes mainly manifested by glucose metabolism disorders caused by genetic and environmental factors. The prevalence of diabetes is increasing rapidly all over the world, especially in developing countries. Diabetes has become a major clinical endocrine and metabolic disease. Diabetes is mainly type 1 and type 2, and the proportion of special type and gestational diabetes is very small. Type 1 diabetes is mainly caused by immune-mediated reduction of islet β cells, while type 2 diabetes gradually reduces the number of islet β cells as the disease progresses. At present, the treatment of diabetes ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/26A61K35/44A61P3/10A61K35/28
Inventor 王颜刚
Owner HOSPITAL ATTACHED TO QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com